NuCana is trading at $0.95, down 6.87%, amid broad market and biotech losses; no company-specific catalyst for November 5, 2026, was identified in available search results. - Reuters reported broad U.S. stock losses and a 3.09% decline in the Nasdaq Composite at 9:57 a.m. ET. - Biotech ETF XBI was down 5.19%; the latest listed NuCana news was from earlier periods.